Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug

26 August 2026 · By · Wire by Fusion42

Published

26 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at ajmc.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

The FDA approved daraxonrasib, the first targeted oral therapy for metastatic pancreatic adenocarcinoma, based on a trial showing it doubled median overall survival versus chemotherapy and had a better safety profile.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.

◆ ◆ The Wire takeaway

Your pancreatic cancer therapies face a new benchmark with daraxonrasib showing survival gains and tolerability improvements. Expect rapid shifts in clinical adoption and competition around RAS-targeted drugs.

◆ Coverage

48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalpancreatic-cancertargeted-therapyras-inhibitor